Companies
Bio-Rad Laboratories
US life-science products company (NYSE: BIO, est. 1952) — Nuvia mixed-mode and ion-exchange chromatography resins, NGC FPLC systems, CHT Ceramic Hydroxyapatite for mAb polishing; broad diagnostics and life-science research portfolio alongside biopharma purification business.
- Country
- United States
- Revenue
- $2.8B
- Employees
- ~7,800 emp
ISO 9001
FDA GMP
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| diagnostics-medtech | ✓ | ✓ | ✓ | ✓ |
| downstream-purification | ✓ | ✓ | — | ✓ |
| education-workforce | ✓ | ✓ | — | ✓ |
| monitoring-conservation | ✓ | ✓ | — | ✓ |
Regulatorsfdareachnmpaepaadememoa-chinaema
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Revenue | $2.58 billion in 2025 | sec.gov |
| Headcount | approximately 7,450 employees as of December 31, 2025 | sec.gov |
| Production site | Global manufacturing network including facilities in Hercules and Irvine (California), Seattle/Woodinville (Washington), Singapore, France, Germany, Switzerland, Belgium, and China | bio-rad.com · sec.gov |
| Certification | ISO 9001, ISO 13485:2016, and Medical Device Single Audit Program (MDSAP) compliance | bio-rad.com · sec.gov |
| Regulatory approval | Products subject to FDA (CDRH/CBER) regulation; diagnostic products meet EU IVDR requirements | sec.gov |
| Funding | Invested in Geneoscopy and Oncocyte; announced intent to acquire Stilla Technologies (as of February 2025) medium confidence | investors.bio-rad.com · sec.gov |
| Capacity | Production capacity is managed based on normal facility capacity; impacted by consolidations of manufacturing sites (e.g., European sites into Singapore hub) medium confidence | bio-rad.com |
Independent sources: sec.gov
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Downstream Purification & Bioseparation | downstream-purification | Low | → |
| Home DNA extraction kits | education-workforce | Low | → |
| Invasive-species biomonitoring via eDNA | monitoring-conservation | Low | → |
| Wastewater-based epidemiology | diagnostics-medtech | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.